Whalesbook
Bristol Myers Squibb Embraces AI for India Growth
Bristol Myers Squibb is positioning India as a key growth engine, entering a period of significant pipeline activity and utilizing artificial intelligence to transform pharmaceutical commercialization.
The company, which achieved over $48 billion in sales last year, anticipates numerous global data readouts over the next 12-18 months across its drugs in oncology, haematology, cardiovascular, and immunology. This expansion comes as BMS scales up its presence in India with new launches like mavacamten (Camzyos) for hypertrophic cardiomyopathy and an expanding oncology portfolio.
Pipeline Expansion and Innovation
The robust pipeline includes promising treatments such as iberdomide and marizomib for multiple myeloma, milvexian for cardiovascular disease aimed at stroke prevention and atrial fibrillation, GPRC5D, a novel cell therapy agent, and melpront for pulmonary fibrosis. These developments underscore BMS's commitment to addressing critical health needs.
AI-Driven Commercialization Hub
BMS is investing over $100 million in AI-led commercialization. Its recently launched Gen AI hub in partnership with Accenture in Mumbai is central to this strategy. The hub is designed to drastically shorten drug commercialization timelines, reducing the time to update prescribers on new clinical trial data from five to six months to as little as two weeks. This acceleration also enables more personalized engagement with physicians and patients globally.
India's Strategic Role
"India is an important market where we've seen strong growth, great performance, and we're looking to bring more and more products here to help more patients," stated Adam Lenkowsky, executive vice-president and chief commercialisation officer at BMS. He emphasized that India is not being used as a backend office but as a leading innovation center. Anvita Karara, head of AI commercial transformation at BMS, confirmed, "The Mumbai team is leading AI. That is true innovation-innovation that is going to power how we think differently and how we work differently."
Preparing for Future Growth
This focus on AI is also part of BMS's strategy to prepare for the eventual loss of exclusivity for its blockbuster drugs. While immuno-oncology drug Opdivo continues to perform strongly globally, the company faces a patent cliff later this decade. To ensure sustained growth beyond 2030, BMS is prioritizing its pipeline, which includes bispecifics, next-generation cell therapies, and cardiovascular and immunology assets. Lenkowsky highlighted the opportunity to launch potentially ten new medicines and 30 new indications across their pipeline, calling it the most robust pipeline in his nearly 30-year career.
Impact
This strategic adoption of AI in drug commercialization by a major biopharma player like Bristol Myers Squibb could set new industry standards for speed and efficiency. For India, it signifies a growing role in global pharmaceutical innovation and quicker access to advanced therapies for patients. The increased investment in AI capabilities within the country could spur further technological advancements in the healthcare sector.
Impact Rating: 7/10